Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw strong trading volume on Tuesday . 73,702 shares traded hands during trading, an increase of 30% from the previous session’s volume of 56,554 shares.The stock last traded at $8.06 and had previously closed at $8.18.

Several equities research analysts have issued reports on the company. Rodman & Renshaw restated a “buy” rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Friday, May 13th. Aegis reiterated a “buy” rating and issued a $18.00 price target on shares of Oramed Pharmaceuticals in a report on Wednesday, May 18th. Finally, FBR & Co boosted their price target on Oramed Pharmaceuticals from $15.00 to $20.00 and gave the company an “outperform” rating in a report on Thursday, May 26th. Six investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $22.00.

The firm’s 50 day moving average price is $8.33 and its 200 day moving average price is $7.71. The stock’s market capitalization is $105.58 million.

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.